Stock Market News
Complexion brightens for SkinBioTherapeutics as company scores material transfer agreement
Life science company SkinBioTherapeutics has signed a material transfer agreement relating to its SkinBiotix technology with a major global consumer goods company, the firm announced on Tuesday.
The agreement with the unnamed company, which could lead to a commercial agreement, has been reached following the skin health specialists decision to share pre-clinical data with a number of interested parties.
The current material transfer agreement will see the consumer goods company assess the SkinBiotix technology before SkinBioTherapeutics moves forward with human studies later this year.
Cath O'Neill, chief executive of SkinBioTherapeutics, said: "Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry."
The company is initially targeting cosmetic skin care with SkinBiotix, which has demonstrated an ability to improve the skin barrier, enhance protection and protect from infection.
Potential opportunities for the technology include cosmetics, anti-infectives and treatment for conditions such as eczema.
As of 0937 BST, SkinBio Therapeutics' shares were up 5.88% at 9.00p.
The agreement with the unnamed company, which could lead to a commercial agreement, has been reached following the skin health specialists decision to share pre-clinical data with a number of interested parties.
The current material transfer agreement will see the consumer goods company assess the SkinBiotix technology before SkinBioTherapeutics moves forward with human studies later this year.
Cath O'Neill, chief executive of SkinBioTherapeutics, said: "Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry."
The company is initially targeting cosmetic skin care with SkinBiotix, which has demonstrated an ability to improve the skin barrier, enhance protection and protect from infection.
Potential opportunities for the technology include cosmetics, anti-infectives and treatment for conditions such as eczema.
As of 0937 BST, SkinBio Therapeutics' shares were up 5.88% at 9.00p.
Related share prices |
---|
SkinBioTherapeutics (SBTX) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price